About the Event
In this installment of the Department of Ophthalmology and Mitchel and Shannon Wong Eye Institute’s Continuing Medical Education Series, Anthony Aldave, M.D., presents “Molecular, Cell and Gene-Based Therapies for the Corneal Endothelial Dystrophies.” Aldave holds the Bartly J. Mondino, M.D., Endowed Chair in Ophthalmology and is a professor in ophthalmology at UCLA David Geffen School of Medicine.
In-person attendees are encouraged to attend at 5 p.m. for a reception prior to the lecture that begins at 6 p.m.
Email Nicole Groote for more information.
Learning Objectives
By the end of this presentation, the audience participant should be able to:
- Describe novel molecular therapies for Fuchs endothelial corneal dystrophy.
- Outline the use of cultured allogenic human corneal endothelial cells to treat corneal endothelial dysfunction in Fuchs endothelial corneal dystrophy and pseudophakic corneal edema.
- Describe gene-based therapeutic approaches to treating congenital hereditary endothelial corneal dystrophy.
Target Audience
- Primary: Physicians in ophthalmology
- Secondary: Any discipline physicians and physician extenders
Attributes/Competencies
This activity has been designed to promote some of the following desired physician attributes and competencies:
- ACGME: Patient Care, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-Based Learning and Improvement Systems-Based Practice
- IOM: Patient-Centered Care, Work with Interdisciplinary Teams, Use Evidence-Based Practice, Apply Quality Improvement, Use informatics
- IECC: Interprofessional Teamwork and Team-Based Practice, Interprofessional Communication, Roles and Responsibilities
Speaker Disclosure
Anthony Aldave, M.D., speaker for this educational activity, receives consulting fees/honoraria for ongoing services from Alcon, Ascidian Therapeutics, ClearView Healthcare Partners, Dompe, EyeYon, GenEditBio Ltd., Glaukos Guidepoint, Kala Pharmaceuticals Inc., SIFI, Surrozen, Thea Pharmaceuticals and W. L. Gore and Associates. He received honoraria from Cornea Society, Massachusetts Eye and Ear Infirmary, National Institutes of Health Oregon Academy of Ophthalmology and Stanford University. Aldave received research funding from California Institute for Regenerative Medicine, Combangio (Kala Pharmaceuticals), Department of Defense National Eye Institute and Research to Prevent Blindness Santen Pharmaceuticals.
Planner Disclosure
Jane Edmond, M.D.; Eileen Bowden, M.D.; Eric Crowell, M.D., MPH; Saleema Kherani-Ali, M.D., MPH; and Nicole Groote, planners of this educational activity, have no relevant relationship(s) with ineligible companies to disclose.
The CME Advisory Committee, reviewers of this educational activity, have no relevant relationships with ineligible companies to disclose.
All the relevant financial relationships listed for these individuals have been mitigated.
Accreditation Statement
The University of Texas at Austin Dell Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas at Austin Dell Medical School designates this internet live course for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.